Compare AGO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGO | EWTX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2003 | 2021 |
| Metric | AGO | EWTX |
|---|---|---|
| Price | $81.83 | $31.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $101.67 | $37.38 |
| AVG Volume (30 Days) | 254.4K | ★ 721.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ 49.34 | N/A |
| EPS | ★ 10.26 | N/A |
| Revenue | ★ $1,110,000,000.00 | N/A |
| Revenue This Year | $3.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.96 | ★ N/A |
| Revenue Growth | ★ 27.29 | N/A |
| 52 Week Low | $74.09 | $10.60 |
| 52 Week High | $92.40 | $31.82 |
| Indicator | AGO | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 60.86 |
| Support Level | $79.57 | $26.91 |
| Resistance Level | $83.39 | N/A |
| Average True Range (ATR) | 1.54 | 1.50 |
| MACD | -0.28 | 0.11 |
| Stochastic Oscillator | 20.95 | 83.18 |
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.